[HTML][HTML] Study of the role of neuropilin-1 in the development, prognosis and cellular response to lenvatinib in human hepatocellular carcinoma
PF Palanca - 2023 - dialnet.unirioja.es
Hepatocellular carcinoma (HCC), the main type of primary liver cancer, constitutes the sixth
most common and third most deadly cancer worldwide, respectively. Due to the late …
most common and third most deadly cancer worldwide, respectively. Due to the late …
[HTML][HTML] Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation
P Fernández-Palanca, T Payo-Serafín… - Acta pharmacologica …, 2023 - nature.com
Despite pharmacological advances such as lenvatinib approval, therapeutic failure of
hepatocellular carcinoma (HCC) remains a big challenge due to the complexity of its …
hepatocellular carcinoma (HCC) remains a big challenge due to the complexity of its …
Inhibition of neuropilin-1 enhances the therapeutic effects of lenvatinib in suppressing cholangiocarcinoma cells via the c-Met pathway
C Zheng, H Wang, S Zhao, C Ma, H Gao, F Yang… - European Journal of …, 2022 - Elsevier
Abstract Neuropilin-1 (NRP-1) participates in the progression of cholangiocarcinoma (CCA)
and lenvatinib is an approved tyrosine kinase inhibitor treating several other cancers. Our …
and lenvatinib is an approved tyrosine kinase inhibitor treating several other cancers. Our …
[PDF][PDF] Role of autophagy-mediated neuropilin-1 degradation on lenvatinib efficacy in human hepatocarcinoma
P Fernández-Palanca, T Payo-Serafín… - Journal of …, 2022 - postersessiononline.eu
Results Page 1 ILC2022 Scan to download the poster #ILSa THE INTERNA TIONAL TM LIVER
CONGRESS P. FERNÁNDEZ-PALANCA1,2, T. PAYO-SERAFÍN1,2, F. FONDEVILA1,2, C …
CONGRESS P. FERNÁNDEZ-PALANCA1,2, T. PAYO-SERAFÍN1,2, F. FONDEVILA1,2, C …
966P Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
T Payo-Serafín, PF Palanca, CM Blanco… - Annals of …, 2023 - annalsofoncology.org
Background Hepatocellular carcinoma (HCC) represents the third most deadly cancer
worldwide with still high therapeutic failure and recurrence rates mainly associated with the …
worldwide with still high therapeutic failure and recurrence rates mainly associated with the …
[HTML][HTML] Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications
P Fernández-Palanca, T Payo-Serafín… - Clinical and …, 2023 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is one of the most common and deadly cancers worldwide
and is characterized by complex molecular carcinogenesis. Neuropilins (NRPs) NRP1 and …
and is characterized by complex molecular carcinogenesis. Neuropilins (NRPs) NRP1 and …
P-141 Lenvatinib activates potential anti-tumor immunity by increasing infiltration of immune cells and interferon response in tumor microenvironment of advanced …
M Yamauchi, A Ono, K Amioka, Y Fujii… - Annals of …, 2022 - annalsofoncology.org
Background It has been reported that the combination of lenvatinib, a multiple receptor
tyrosine kinase inhibitor, and an immune checkpoint inhibitor enhances the antitumor activity …
tyrosine kinase inhibitor, and an immune checkpoint inhibitor enhances the antitumor activity …
[HTML][HTML] Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited …
Nuclear factor-kappa B (NF-κB), an oncogenic transcription factor, modulates tumor
formation and progression by inducing the expression of oncogenes involved in …
formation and progression by inducing the expression of oncogenes involved in …
[HTML][HTML] Overexpression of the lncRNA HOTAIRM1 promotes lenvatinib resistance by downregulating miR-34a and activating autophagy in hepatocellular carcinoma
D Gu, M Tong, J Wang, B Zhang, J Liu, G Song… - Discover Oncology, 2023 - Springer
Background Hepatocellular carcinoma (HCC) is one of the most common malignant cancers
in humans and has a high fatality rate. Despite pharmacological advances such as sorafenib …
in humans and has a high fatality rate. Despite pharmacological advances such as sorafenib …
[HTML][HTML] Tumor fibroblast growth factor receptor 4 level predicts the efficacy of lenvatinib in patients with advanced hepatocellular carcinoma
M Yamauchi, A Ono, A Ishikawa… - Clinical and …, 2020 - journals.lww.com
OBJECTIVES: Biomarkers for optimizing the outcome of treatment with lenvatinib in patients
with advanced hepatocellular carcinoma remain to be established despite intensive and …
with advanced hepatocellular carcinoma remain to be established despite intensive and …
相关搜索
- neuropilin 1 cellular response
- neuropilin 1 carcinoma patients
- lenvatinib resistance hepatocellular carcinoma
- carcinoma cells lenvatinib efficacy
- neuropilin 1 lenvatinib efficacy
- neuropilin 1 human hepatocarcinoma
- immune cells interferon response
- neuropilin 1 therapeutic effects
- lncrna hotairm1 hepatocellular carcinoma
- neuropilin 1 risk of invasion
- human hepatocarcinoma lenvatinib efficacy
- neuropilin 1 cholangiocarcinoma cells